Literature DB >> 8923498

Effects of non-peptide angiotensin II-receptor antagonists on pentylenetetrazol kindling in mice.

V P Georgiev1, M B Lazarova, T S Kambourova.   

Abstract

The effects of non-peptide AT1- and AT2-receptor antagonists DuP 753 (losartan) and PD 123319 on the intensity of pentylenetetrazol (PTZ)-kindled seizures in mice were studied. PTZ was injected intraperitoneally at a subconvulsive dose of 40 mg/kg at 48 h until the appearance of clonic seizures. DuP 753 administered intracerebroventricularly (i.c.v.) tended to decrease seizure intensity. Successive administration of ineffective doses of DuP 753 (losartan) and AT2 (angiotensin II) significantly decreased seizure intensity. PD 123319 (i.c.v.) decreased seizure intensity. Combination of ineffective doses of PD 123319 and AT2 also significantly decreased seizure intensity. The results suggest the role of AT2 receptor and its subtypes in PTZ-kindled seizures as well as an action of DuP 753 and PD 123319 similar to the action of AT2, an AT2-receptor agonist.

Entities:  

Mesh:

Substances:

Year:  1996        PMID: 8923498     DOI: 10.1016/s0143-4179(96)90000-1

Source DB:  PubMed          Journal:  Neuropeptides        ISSN: 0143-4179            Impact factor:   3.286


  3 in total

1.  Long-Term Treatment with Losartan Attenuates Seizure Activity and Neuronal Damage Without Affecting Behavioral Changes in a Model of Co-morbid Hypertension and Epilepsy.

Authors:  Jana D Tchekalarova; Natasha Ivanova; Dimitrina Atanasova; Daniela M Pechlivanova; Nikolai Lazarov; Lidia Kortenska; Rumiana Mitreva; Valentin Lozanov; Alexander Stoynev
Journal:  Cell Mol Neurobiol       Date:  2015-10-13       Impact factor: 5.046

Review 2.  From the Molecular Mechanism to Pre-clinical Results: Anti-epileptic Effects of Fingolimod.

Authors:  Yam Nath Paudel; Efthalia Angelopoulou; Christina Piperi; Vadym Gnatkovsky; Iekhsan Othman; Mohd Farooq Shaikh
Journal:  Curr Neuropharmacol       Date:  2020       Impact factor: 7.363

Review 3.  Neuropeptides as targets for the development of anticonvulsant drugs.

Authors:  Elke Clynen; Ann Swijsen; Marjolein Raijmakers; Govert Hoogland; Jean-Michel Rigo
Journal:  Mol Neurobiol       Date:  2014-04-06       Impact factor: 5.590

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.